InsidersTradesSigma
Total declarations
Company
▲ Purchases (1 ops.)
▼ Sales (1 ops.)
Explore the detailed record of transactions filed by emmanuel huynh, Chairman of the Board of Directors / Chairman of the Audit Committee. Director active across 1 companies, notably Abionyx Pharma. Cumulatively, 3 disclosures have been published. Total volume traded: €32k. The latest transaction was disclosed on 17 December 2025 — Cession. Regulator: AMF. All data is free.
Declarations3 total
€32,35010,000 shares@ €3.2350.024% mcap100.0% of flow
ActionEuronext Paris
2025DD1086325·
0125,000 shares0
ActionEuronext Paris
2022DD872749·
Ideal exit: 15 Aug 2023 (T+270)
€749,999208,333 shares@ €3.60100.0% of flow
ActionEuronext Paris
2021DD801177·
3 of 3 declarations
About emmanuel huynh
Emmanuel Huynh is a well-known French corporate governance and investor-relations executive, particularly recognized in the listed-company ecosystem. At ABIONYX Pharma, he serves as Chairman of the Board of Directors and also chairs the Audit Committee, placing him at the center of the company’s strategic and financial oversight. His appointment as a director was approved at the Ordinary General Meeting held on 26 August 2019, as the company entered a new phase of development. Huynh’s background combines finance, strategy and public-policy training. He holds a Maîtrise in Management Sciences, a Sciences Po Paris degree in economics/finance, and a postgraduate DEA in Political Science. He began his career in investment banking and in the finance departments of large industrial groups, before moving into advisory work for listed companies. This path gave him a strong understanding of capital markets, financial communication, shareholder dialogue and governance standards. He is best known as the co-founder and former Managing Director of NewCap, a French investor-relations and financial-communication advisory firm, which he led for 25 years. That long tenure made him a seasoned specialist in listed-company communications, market messaging and stakeholder engagement. In parallel, he serves as General Delegate of Club F, described by ABIONYX as France’s first think tank dedicated to the Family Office community, underscoring his involvement in long-term wealth, ownership and governance topics. At ABIONYX Pharma, his value lies in his financial expertise and business acumen. The company highlighted his critical financial skills and deep business expertise when he joined the board. His role supports a biotechnology group focused on innovative therapies for areas with limited or no effective treatment options, including ophthalmology and renal disease. By bringing capital-markets experience, governance discipline and investor-relations insight, Huynh helps reinforce ABIONYX Pharma’s credibility with shareholders and its strategic execution as a listed biotech company.